Weihao Yang, Mengting Lu, Wangjiao He, Wenjun He, Xin Tan, Hengyi Zhang, Fengping Li, Liying Zhao, Ye Dong, Hao Liu
{"title":"Imaging Characteristics and Clinical Outcomes in Gastric Cancer with Brain Metastasis: A Propensity Score-Matched Study.","authors":"Weihao Yang, Mengting Lu, Wangjiao He, Wenjun He, Xin Tan, Hengyi Zhang, Fengping Li, Liying Zhao, Ye Dong, Hao Liu","doi":"10.1007/s12029-025-01284-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the impact of brain metastasis (BM) on the clinical outcomes of gastric cancer (GC) and explored related imaging characteristics.</p><p><strong>Methods: </strong>GC patients of tumor stage IV treated at Nanfang Hospital from October 2004 to September 2022 were included. The comparisons of non-BM and BM group were used by propensity score matching (PSM). The Kaplan-Meier method was used to compare the overall survival (OS) and cancer-specific survival (CSS). Cox regression was used for multivariate analyses.</p><p><strong>Results: </strong>A total of 1,051 patients were included. After PSM, non-BM group (n = 28) and BM group (n = 28) were more balanced in baseline variables. The OS (p < 0.05) and CSS (p < 0.05) of the BM group were inferior to those of the non-BM group. Multivariate Cox regression analysis suggests that brain metastasis is associated with poor OS (HR = 1.959, 95% CI: 1.031-3.721, p = 0.040) and CSS (HR = 1.988, 95% CI: 1.037-3.812, p = 0.038). Brain metastases predominantly occur in the frontal lobe (68.0%), followed by the parietal lobe (52.0%), and cerebellum (36.0%), these metastases frequently present with associated edema (65.1%) and necrosis (33.7%).</p><p><strong>Conclusion: </strong>The presence of brain metastasis is associated with poor OS and CSS. Brain metastases from GC commonly occur in the frontal lobe, parietal lobe, and cerebellum, with frequent imaging features of edema and necrosis.</p>","PeriodicalId":15895,"journal":{"name":"Journal of Gastrointestinal Cancer","volume":"56 1","pages":"157"},"PeriodicalIF":1.6000,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Gastrointestinal Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12029-025-01284-y","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose: This study aimed to investigate the impact of brain metastasis (BM) on the clinical outcomes of gastric cancer (GC) and explored related imaging characteristics.
Methods: GC patients of tumor stage IV treated at Nanfang Hospital from October 2004 to September 2022 were included. The comparisons of non-BM and BM group were used by propensity score matching (PSM). The Kaplan-Meier method was used to compare the overall survival (OS) and cancer-specific survival (CSS). Cox regression was used for multivariate analyses.
Results: A total of 1,051 patients were included. After PSM, non-BM group (n = 28) and BM group (n = 28) were more balanced in baseline variables. The OS (p < 0.05) and CSS (p < 0.05) of the BM group were inferior to those of the non-BM group. Multivariate Cox regression analysis suggests that brain metastasis is associated with poor OS (HR = 1.959, 95% CI: 1.031-3.721, p = 0.040) and CSS (HR = 1.988, 95% CI: 1.037-3.812, p = 0.038). Brain metastases predominantly occur in the frontal lobe (68.0%), followed by the parietal lobe (52.0%), and cerebellum (36.0%), these metastases frequently present with associated edema (65.1%) and necrosis (33.7%).
Conclusion: The presence of brain metastasis is associated with poor OS and CSS. Brain metastases from GC commonly occur in the frontal lobe, parietal lobe, and cerebellum, with frequent imaging features of edema and necrosis.
期刊介绍:
The Journal of Gastrointestinal Cancer is a multidisciplinary medium for the publication of novel research pertaining to cancers arising from the gastrointestinal tract.The journal is dedicated to the most rapid publication possible.The journal publishes papers in all relevant fields, emphasizing those studies that are helpful in understanding and treating cancers affecting the esophagus, stomach, liver, gallbladder and biliary tree, pancreas, small bowel, large bowel, rectum, and anus. In addition, the Journal of Gastrointestinal Cancer publishes basic and translational scientific information from studies providing insight into the etiology and progression of cancers affecting these organs. New insights are provided from diverse areas of research such as studies exploring pre-neoplastic states, risk factors, epidemiology, genetics, preclinical therapeutics, surgery, radiation therapy, novel medical therapeutics, clinical trials, and outcome studies.In addition to reports of original clinical and experimental studies, the journal also publishes: case reports, state-of-the-art reviews on topics of immediate interest or importance; invited articles analyzing particular areas of pancreatic research and knowledge; perspectives in which critical evaluation and conflicting opinions about current topics may be expressed; meeting highlights that summarize important points presented at recent meetings; abstracts of symposia and conferences; book reviews; hypotheses; Letters to the Editors; and other items of special interest, including:Complex Cases in GI Oncology: This is a new initiative to provide a forum to review and discuss the history and management of complex and involved gastrointestinal oncology cases. The format will be similar to a teaching case conference where a case vignette is presented and is followed by a series of questions and discussion points. A brief reference list supporting the points made in discussion would be expected.